Aura Biosciences (AURA) News Today $7.51 -0.12 (-1.57%) Closing price 04:00 PM EasternExtended Trading$7.71 +0.20 (+2.66%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Analysts Are Bullish on These Healthcare Stocks: Aura Biosciences Inc (AURA), Springworks Therapeutics (SWTX)February 20 at 2:32 PM | markets.businessinsider.comAura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Buy" from AnalystsShares of Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) have been assigned a consensus rating of "Buy" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating toFebruary 20 at 4:11 AM | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) SVP Sells $10,881.00 in StockAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) SVP Amy Elazzouzi sold 1,404 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total transaction of $10,881.00. Following the transaction, the senior vice president now directly owns 82,278 shares in the company, valued at approximately $637,654.50. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.February 19 at 8:49 PM | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) CTO Sells $16,670.25 in StockAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) CTO Mark Plavsic sold 2,151 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total value of $16,670.25. Following the completion of the sale, the chief technology officer now owns 209,456 shares in the company, valued at approximately $1,623,284. The trade was a 1.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.February 19 at 8:49 PM | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Insider Janet Jill Hopkins Sells 2,534 SharesAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Janet Jill Hopkins sold 2,534 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total transaction of $19,638.50. Following the completion of the sale, the insider now owns 269,794 shares of the company's stock, valued at approximately $2,090,903.50. The trade was a 0.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.February 19 at 8:49 PM | marketbeat.comInsider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) SVP Sells 1,404 Shares of StockFebruary 19 at 4:49 AM | insidertrades.comAura Biosciences, Inc. (NASDAQ:AURA) Short Interest Down 14.2% in JanuaryAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) was the target of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 1,210,000 shares, a decrease of 14.2% from the January 15th total of 1,410,000 shares. Based on an average daily volume of 179,200 shares, the short-interest ratio is presently 6.8 days. Currently, 2.7% of the shares of the stock are short sold.February 17, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for AURA FY2025 Earnings?Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2025 EPS estimates for shares of Aura Biosciences in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earningsFebruary 10, 2025 | marketbeat.comQ1 Earnings Forecast for AURA Issued By Leerink PartnrsAura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Aura Biosciences in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will post earnings per shaFebruary 7, 2025 | marketbeat.comAura Biosciences (NASDAQ:AURA) Upgraded by Lifesci Capital to Strong-Buy RatingLifesci Capital upgraded Aura Biosciences to a "strong-buy" rating in a research report on Friday.February 1, 2025 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Short Interest UpdateAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,280,000 shares, an increase of 20.8% from the December 31st total of 1,060,000 shares. Based on an average daily volume of 206,600 shares, the days-to-cover ratio is currently 6.2 days. Approximately 2.9% of the shares of the stock are sold short.January 31, 2025 | marketbeat.comRegency Capital Management Inc. DE Has $5.01 Million Holdings in Aura Biosciences, Inc. (NASDAQ:AURA)Regency Capital Management Inc. DE lessened its holdings in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 8.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 609,424 shaJanuary 26, 2025 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Receives Consensus Rating of "Buy" from AnalystsAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) has been given an average rating of "Buy" by the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy ratiJanuary 26, 2025 | marketbeat.comWhat is Lifesci Capital's Forecast for AURA FY2024 Earnings?Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Equities researchers at Lifesci Capital issued their FY2024 EPS estimates for Aura Biosciences in a research note issued on Tuesday, January 21st. Lifesci Capital analyst O. Mccammon forecasts that the company will earn ($1.65) per share for thJanuary 24, 2025 | marketbeat.comInsider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 15,955 Shares of StockJanuary 22, 2025 | insidertrades.comAura Biosciences VP Amy Elazzouzi sells $7,679 in stockJanuary 22, 2025 | msn.comAura Biosciences CEO Elisabet de los Pinos sells shares worth $122,381January 22, 2025 | msn.comAura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $122,374.85 in StockAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Los Pinos Elisabet De sold 15,955 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the sale, the insider now directly owns 304,692 shares in the company, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.January 21, 2025 | marketbeat.comBarclays PLC Has $544,000 Position in Aura Biosciences, Inc. (NASDAQ:AURA)Barclays PLC lifted its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 256.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 61,010 shares of the company's stock after purchasing an additional 43,January 18, 2025 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Given Consensus Recommendation of "Buy" by BrokeragesShares of Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) have earned a consensus recommendation of "Buy" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and two have assJanuary 1, 2025 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Shares Purchased by Franklin Resources Inc.Franklin Resources Inc. grew its holdings in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 14.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,668,960 shares of the company's stock aftDecember 21, 2024 | marketbeat.comWellington Management Group LLP Purchases New Holdings in Aura Biosciences, Inc. (NASDAQ:AURA)Wellington Management Group LLP acquired a new stake in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 116,392 shares of the company's stock, valued at approximately $1,037,000. WelDecember 20, 2024 | marketbeat.comBuy Recommendation for Aura Biosciences Inc. Based on Promising Clinical Data and Growth ProspectsDecember 17, 2024 | markets.businessinsider.comAura Biosciences, Inc. (NASDAQ:AURA) Shares Sold by Fmr LLCFmr LLC lowered its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 56.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 101,217 shares of the company's stoDecember 17, 2024 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Sees Large Increase in Short InterestAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 1,030,000 shares, an increase of 8.8% from the November 15th total of 947,100 shares. Based on an average trading volume of 202,000 shares, the short-interest ratio is presently 5.1 days. Approximately 2.4% of the shares of the stock are short sold.December 15, 2024 | marketbeat.comXoma (XOMA) Receives a Hold from TD CowenDecember 2, 2024 | markets.businessinsider.comMuscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGenDecember 2, 2024 | globenewswire.comAura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNovember 26, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (HIMS) and Celcuity (CELC)November 19, 2024 | markets.businessinsider.comAura Biosciences, Inc. (NASDAQ:AURA) Insider Janet Jill Hopkins Sells 11,822 SharesNovember 19, 2024 | insidertrades.comHC Wainwright Forecasts Higher Earnings for Aura BiosciencesAura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Analysts at HC Wainwright boosted their FY2024 earnings estimates for Aura Biosciences in a report issued on Wednesday, November 13th. HC Wainwright analyst E. White now expects that the company will earn ($1.69) per share for the year, up fromNovember 18, 2024 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 7.6% in OctoberAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,130,000 shares, a growth of 7.6% from the October 15th total of 1,050,000 shares. Based on an average daily trading volume, of 163,000 shares, the days-to-cover ratio is currently 6.9 days. Currently, 2.7% of the company's shares are short sold.November 17, 2024 | marketbeat.comResearch Analysts Set Expectations for AURA FY2024 EarningsAura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Stock analysts at Leerink Partnrs upped their FY2024 earnings estimates for Aura Biosciences in a report issued on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($1.67November 15, 2024 | marketbeat.comAura Biosciences Reports Q3 Financial ResultsNovember 15, 2024 | markets.businessinsider.comPromising Pipeline Developments and Regulatory Milestones Justify Buy Rating for Aura Biosciences IncNovember 15, 2024 | markets.businessinsider.comAura Biosciences (NASDAQ:AURA) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $22.00 price target on shares of Aura Biosciences in a research report on Thursday.November 14, 2024 | marketbeat.comBuy Rating for Aura Biosciences Inc Driven by Promising Clinical Progress and Strategic GrowthNovember 13, 2024 | markets.businessinsider.comShort Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Decreases By 8.7%Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 1,050,000 shares, a decline of 8.7% from the September 30th total of 1,150,000 shares. Approximately 2.5% of the company's shares are sold short. Based on an average trading volume of 184,900 shares, the days-to-cover ratio is currently 5.7 days.October 30, 2024 | marketbeat.comInsider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 9,200 Shares of StockOctober 30, 2024 | insidertrades.comAura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $98,808.00 in StockAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Los Pinos Elisabet De sold 9,200 shares of the business's stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $10.74, for a total transaction of $98,808.00. Following the completion of the sale, the insider now directly owns 320,647 shares in the company, valued at approximately $3,443,748.78. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.October 29, 2024 | marketbeat.comAura Biosciences (NASDAQ:AURA) Stock Price Down 4.9% After Insider SellingAura Biosciences (NASDAQ:AURA) Shares Down 4.9% Following Insider SellingOctober 22, 2024 | marketbeat.comPromising Phase 1 Results and Strong Safety Profile of Bel-sar Support Buy Rating for Aura Biosciences IncOctober 22, 2024 | markets.businessinsider.comAura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder ValueOctober 22, 2024 | seekingalpha.comAura Biosciences, Inc. (NASDAQ:AURA) CFO Sells $302,325.93 in StockOctober 22, 2024 | insidertrades.comDiet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies RetractedOctober 20, 2024 | msn.comLos Pinos Elisabet De Sells 24,992 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) StockOctober 19, 2024 | insidertrades.comInsider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 24,992 Shares of StockAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Los Pinos Elisabet De sold 24,992 shares of the firm's stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $12.04, for a total value of $300,903.68. Following the transaction, the insider now owns 329,847 shares in the company, valued at approximately $3,971,357.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.October 18, 2024 | marketbeat.comPromising Phase 1 Trial Results for Aura Biosciences Inc.’s Bel-sar Support Buy RatingOctober 18, 2024 | markets.businessinsider.comTD Cowen Remains a Buy on Aura Biosciences Inc (AURA)October 18, 2024 | markets.businessinsider.comAura Biosciences' Shares Touch 52-Week High on Positive Cancer Drug DataOctober 18, 2024 | marketwatch.com Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address AURA Media Mentions By Week AURA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AURA News Sentiment▼0.780.60▲Average Medical News Sentiment AURA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AURA Articles This Week▼102▲AURA Articles Average Week Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amphastar Pharmaceuticals News Today Galapagos News Today Dyne Therapeutics News Today Immunocore News Today Kiniksa Pharmaceuticals News Today Structure Therapeutics News Today Nurix Therapeutics News Today Arcutis Biotherapeutics News Today Ardelyx News Today Indivior News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AURA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersHere’s how you could profit from Elon’s NVIDIA partnership"Elon's #1 AI Stock" SET TO SOAR Forget ChatGPT! Because Elon Musk's AI promises to be 100x more powerfu...Behind the Markets | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
